AEON — Aeon Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $9.73m
- $20.86m
Annual cashflow statement for Aeon Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -55.6 | -52.6 | -385 | 42 |
| Depreciation | ||||
| Non-Cash Items | 25.8 | 10.6 | 339 | -63.1 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 1.42 | 6.27 | -2.74 | 0.706 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Net Change in Other Assets & Liabilities | ||||
| Cash from Operating Activities | -28.4 | -35.6 | -47.8 | -20.3 |
| Capital Expenditures | -0.17 | -0.306 | 0 | — |
| Purchase of Fixed Assets | ||||
| Cash from Investing Activities | -0.17 | -0.306 | 0 | — |
| Financing Cash Flow Items | -1.44 | 0 | — | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 13.6 | 40.5 | 14 | 15.1 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -15 | 4.62 | -33.8 | -5.14 |